Ketamine Low-dose Evaluation on Morphine Consumption in Traumatic Patients (KLOE)

Randomised, parallel-group, quadruple-blind Phase III trial comparing low-dose ketamine (bolus 0.1 mg/kg then 0.15 mg/kg/hr infusion for 48 hours) with placebo in traumatic patients to reduce opioid consumption.

Primary outcome is reduction in opioid (morphine) consumption at 48 hours; analgesia non-inferiority and safety/tolerability will also be assessed.